Printed From BioPortfolio.com

Roche gets FDA approval for Ventana ALK CDx assay to identify lung cancer patients eligible for treatment with Alecensa

03:11 EST 8 Nov 2017 | Medical Business Review

Roche has obtained US Food and Drug Administration (FDA) approval for the Ventana ALK (D5F3) CDx assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer (NSCLC) patients eligible for treatment with the Roche medicine ALECENSA (alectinib).

Original Article: Roche gets FDA approval for Ventana ALK CDx assay to identify lung cancer patients eligible for treatment with Alecensa

More From BioPortfolio on "Roche gets FDA approval for Ventana ALK CDx assay to identify lung cancer patients eligible for treatment with Alecensa"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

News Quicklinks

Search Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches